Ankylosing spondylitis - adalimumab, etanercept and infliximab: review decision - November 2012
Review of NICE Technology Appraisal Guidance No. 143; Adalimumab, etanercept and infliximab for ankylosing spondylitis
The Institute was proposing that an update of TA143 should take place in the context of a multiple technology appraisal to include:
- a broadening of the indication to include axial spondyloarthritis without radiographic evidence of ankylosing spondylitis’
- all TNF-inhibitors that are licensed for the relevant indications or that will be licensed within the timeline of the appraisal.
This expanded remit would encompass an update of TA233 ‘Golimumab for the treatment of ankylosing spondylitis’ which was due to be considered for review in August 2014.
During consultation, the majority of comments received by the Institute agreed with the proposal put forward. After consideration of all of the comments (attached as appendix A), the Institute’s Guidance Executive has decided to proceed with the proposal. Consequently, we will conduct a review of TA143 and TA233 subject to agreement to the expanded remit by the Department of Health.
This page was last updated: 15 November 2012